Prevalence and Characteristics of Intimate Partner Violence Against Individuals Seeking Hematological Consultations (HEMATO-WAST)

May 13, 2024 updated by: Centre Hospitalier Universitaire de Nīmes

Intimate violence against individuals, which is particularly marked among women, is one of the most widespread human rights violations in the world.

The Women Abuse Screening Tool (WAST) self-questionnaire is a screening tool validated in French.

Our preliminary data describing the association between intimate violence against women and the first attack of unexplained venous thromboembolic disease, show a significant frequency of positive responses to the WAST among women attending a biological hematology consultation at the CHU de Nîmes, for reasons of hemostasis disorders (8% out of the first 200 cases).

The study authors wish to establish the prevalence of this situation among patients presenting to the CHU de Nîmes for hematological exploration and management. They hypothesize that the prevalence of violence against individuals seen in Hematology consultations is higher among individuals with hemostasis pathologies (hemorrhagic and thrombotic pathologies) than those with cellular pathologies, and higher among women than men.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

3240

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Outpatients attending consultations at the CHU de Nîmes for hematological diseases.

Description

Inclusion Criteria:

  • Currently in a relationship or has been in one in the last 12 months, regardless of the length of the relationship
  • Willing to complete the anonymous WAST self-questionnaire
  • able to read and understand French

  • Outpatient consultant at Nîmes University Hospital in one of the following departments:

    • Biological hematology consultation
    • Clinical hematology consultation
    • Vascular medicine consultation

Exclusion Criteria:

  • Individuals under court protection, guardianship or curatorship
  • Individuals unable to read and understand French
  • Individuals who have already completed the WAST questionnaire during the study period
  • Individuals unable to get away from their partner during the consultation to complete the questionnaire in isolation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patients presenting at a biological hematology consultation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of patients experiencing Intimate Partner Violence according to consulting department
Time Frame: Day 0
Percentage of patients with a Women Abuse Screening Tool (WAST) score ≥ 5 consulting in the hemostasis pathology versus cellular hematological pathology department. The WAST is an 8-item questionnaire with a score ranging from 0 to 16 (worst violence), with a cut-off of 5 for presence of violence
Day 0

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of Intimate Partner Violence in men versus women according to consulting department
Time Frame: Day 0
WAST score ≥ 5 consulting in the hemostasis pathology versus cellular hematological pathology department in women versus men
Day 0
Prevalence of Intimate Partner Violence according to patient disease status and gender
Time Frame: Day 0
WAST questionnaire total score in women versus men, for hemostasis disease versus cellular hematological disease versus hemorrhagic symptomatology versus thrombotic symptomatology
Day 0
WAST questionnaire score according to patient disease status and gender
Time Frame: Day 0
Score for individual items of WAST questionnaire in women versus men, for hemostasis disease versus cellular hematological disease versus hemorrhagic symptomatology versus thrombotic symptomatology
Day 0
Association between the major risk factors for Intimate Partner Violence and WAST score.
Time Frame: Day 0
WAST questionnaire total score according to: Number of years together, Violence at home growing up, Marital status (divorced or separated), Children living at home, Working status, Finances (personal income, financial difficulties), Living status (together vs separate, size of dwelling, neighbors nearby), Health status of living partner, Health status of patient
Day 0

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Universitaire de Nīmes

Investigators

  • Principal Investigator: Jean-Christophe Gris, CHU de Nimes

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2024

Primary Completion (Estimated)

June 1, 2025

Study Completion (Estimated)

June 1, 2025

Study Registration Dates

First Submitted

May 13, 2024

First Submitted That Met QC Criteria

May 13, 2024

First Posted (Actual)

May 16, 2024

Study Record Updates

Last Update Posted (Actual)

May 16, 2024

Last Update Submitted That Met QC Criteria

May 13, 2024

Last Verified

May 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NIMAO/2023-2/JCG-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intimate Partner Violence

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe